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Multiple sclerosis (SM) is a chronic inﬂammatory and degenerative disease of the central
nervous system. Its etiology has not been fully elucidated. For approximately 20 years, drugs
have been used, successfully modifying the natural course of relapsing-remitting SM. One of
them is interferon beta. Research outcomes of 16- and 21-year-retrospective follow-up of
patients who participated in the pivotal interferon beta-1b trial were reported in 2010 and
2012, respectively. After 21 years, mortality rate among patients treated in the ﬁrst 5 years
with interferon beta-1b at a dose of 250 mg was signiﬁcantly lower, irrespective of the cause,
as compared to the placebo-controlled group. Interferon beta-1b administered during the
ﬁrst 5 years of the study decreased the risk of death by 46.8% as compared to the placebo
patients. Moreover, the studies also conﬁrmed safety of long-term interferon beta-1b
therapy. However, not much is known about the effect of interferon beta-1a on patients'
survival – the available data are presented in the article.
# 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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journal homepage: http://www.elsevier.com/locate/pjnns1. Life expectancy of patients with multiple
sclerosis – is it a marginalized problem?
Multiple sclerosis (MS) is a chronic inﬂammatory and
degenerative disease of the central nervous system (CNS)
affecting mainly the young [1,2]. Since its etiology still remains
not completely clear, there is no effective causative treatment
[3]. In most patients, the disease leads to psychophysical
disability that reduces the quality of life [4,5]. Permanent
disability arouses the greatest fear among MS patients and
their families. On the other hand, a potential reduction in life
expectancy is relatively seldom discussed both by patients and
doctors. It is commonly believed that MS reduces life quality* Corresponding author at: Department of Neurology, University Hosp
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0028-3843/# 2014 Polish Neurological Society. Published by Elsevier Ubut virtually has no impact on life expectancy. Statements of
that kind can be found on the websites of MS support groups in
various countries, like the one of the Polish Society of Multiple
Sclerosis (PTSR in Polish): However, MS does not affect
life expectancy, being nearly the same as the average length of
human life [6]. Multiple sclerosis is highly heterogenic, and
cases may differ extremely in clinical symptoms, course and
severity. Therefore, long-term registry studies, possibly cov-
ering the whole population of patients in the respective
country or region can serve as the source of information on the
natural course of MS [7]. Danish Multiple Sclerosis Registry
established in 1956 is one of the oldest of that type worldwide
[8,9]. Since the Registry includes all Danish citizens diagnosed
with MS, it is highly reliable. The analysis of mortality dataital, Ul. Skłodowskiej-Curie 24a, 15-276 Białystok, Poland.
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10–12 years shorter compared to the general population, and in
over 50% of the deceased, MS is the reported cause [10]. The
standardized mortality ratio (SMR) is a ratio of the number of
observed deaths in the disease burden group to the number of
deaths in burden-free group. The SMR above 1.0 indicates an
unfavorable effect of the disease on patients' survival. Accord-
ing to the Danish Registry, SMR in the MS group is 3.14 for
women and 2.66 for men [11], as compared to the SMR in an early
breast cancer period 2.0, cirrhosis 2.52 and diabetes 4.47 [12,13].
2. Life expectancy of MS patients in Poland
In Poland, MS cases are not registered on a regular basis, and
epidemiological data on the disease are conﬁned to the
results obtained in a few population studies conducted in
chosen regions of the country or in pilot trials covering
approximately 15% of the entire population of Polish patients
[14–17]. However, in 2011 some extremely interesting
ﬁndings were reported on life expectancy in MS patients in
Poland; unfortunately, the report was published in a minor
journal. Cendrowski [18] carried out a retrospective study to
analyze a long-term tendency of changes in life expectancy
and in C-PSI (Case-to-Population Survival Index) among MS
patients who had died in Poland within nearly a 40-year-
period (1969–2007). The C-PSI was calculated as a quotient of
the average age at death and life expectancy of the Polish
population in the same calendar year. The researcher, using
statistical data of WHO and Central Statistical Ofﬁce (GUS in
Polish) analyzed 18,703 deaths, in which MS was a primary or
secondary cause. In the study period, the average lifespan
extended from 49.4 to 56.5 years in MS male patients and
from 49.2 to 56.4 years in the female ones. However, C-PSI did
not change signiﬁcantly: the Index was found to be 0.72 for
women and 0.79 for men in 1969 versus 0.70 and 0.78 in 2007,
respectively. This indicates a simultaneous increase in life
expectancy of MS patients and in the general population.
Eventually, survival rate among male and female MS
sufferers at the end of the study period (2007) was
respectively by 15 and 23 years shorter (Fig. 1) as compared
to the general population [18].Fig. 1 – Curves illustrating the median survival of MS patients in 
1969–2007.
Figure from the article: Cendrowski W., Terapie specjalistyczne.3. Long-term assessment of
immunomodulatory treatment
Drugs that substantially modify the natural course of relaps-
ing-remitting MS (decreasing the relapse rate and inhibiting
disability progression) have been used for only 20 years now.
Registration of the ﬁrst preparation, interferon beta, in the
1990s was a breakthrough in the treatment of MS [19].
Interferon beta preparations [20,21] were registered after
24-month multi-center, randomized, double blind, clinical
trials which proved short-term efﬁcacy and safety of the drugs
in comparison with placebo, yet did not elucidate their long-
term effects (?). Nowadays, the available registries of patients
also fail to settle the issue [7]; they show, however, that
disability progresses in a predictable manner when EDSS is
over 4, independently of the initial course of the disease
[22,23]. This proves that the therapy should be instituted early
enough to slow down the progression. It seems that the impact
of the immunomodulatory therapy on the natural course of MS
can only be assessed based on well-planned clinical trials
interpreted in the context of patient registry data. Long-term
research of patients undergoing immunomodulatory therapy
provides valuable information on its efﬁcacy and safety.
4. Long-term follow-up of patients treated
with interferon beta-1b
4.1. A 16-year retrospective study
In June 2010, results were reported of a 16-year retrospective
follow-up of patients involved in the clinical research that
initiated interferon 1b marketing in 1993 [24]. Patients with
relapsing-remitting MS participating in the pivotal study
(n = 372) were randomly assigned to 3 study groups, each
receiving either placebo or interferon beta 1b 50 mg or
interferon beta 1b 250 mg subcutaneously every other day.
The aim of the retrospective follow-up was to ﬁnd out any
differences between the three groups 16 years after the
commencement of the pivotal study. Data were collected on
the level of disability as determined by the Expanded Disabilitycomparison to the general population in Poland, in the years
 Bayer HealthCare 2011; 1(1): 18–24.
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Composite Measure (MSFC) [26], relapse rates and conversion to
secondary-progressive MS.
The authors [24] managed to identify 328 out of 372 (88.2%)
patients involved in the pivotal study, among whom 35 turned
out to be deceased (35/328; 10.7%). The analysis of the three
baseline groups of patients (placebo, interferon beta 1b 250 mg
or interferon beta 1b 50 mg) showed evident differences in
mortality rate. Of the 35 deceased patients, twenty had been
in the placebo group (20/109; 18.3%), nine had received inter-
feron beta 1b at a dose of 50 mg (9/108; 8.3%), and six interferon
beta 1b 250 mg (6/111; 5.4%). Interestingly, the cause of death was
known only in 9 out of the 35 cases.
4.2. A 21-year retrospective follow-up study
As patients treated with interferon beta 1b from the very
beginning seemed more likely to survive than those receiving
placebo, an attempt was made to assess all the patients
participating in the pivotal trial after 21.4 years on average
following randomization [27]. The researchers managed to
identify 366 patients (98.4%), of whom 81 were deceased
(37 received placebo at baseline; 22 – interferon 50 mg and
22 – interferon 250 mg). After 21 years, mortality rate was
signiﬁcantly lower in patients treated with a higher dose of
interferon beta 1b at baseline, irrespective of the cause, as
compared to the placebo group (p = 0.0173). The drug de-
creased the risk of death by 46.8% in comparison with the
patients receiving placebo within the ﬁrst 5 years of the study
(Fig. 2).
The lower dose of interferon beta 1b (50 mg) had a similar
beneﬁcial effect on the survival rate [27]. Apparently, the
effect of the drug on patients' survival is not dose-
dependent. Theoretically, this effect may be associated with
antioxidant properties of the drug; however, the issue
requires further research. The mortality rate in the placeboFig. 2 – Curves illustrating survival of patients within a 21-year-
interferon beta 1b and placebo.
Figure from the article: Michalak S., Terapie specjalistyczne. Bay
the authors did not receive any financial support.group at baseline was consistent with the data concerning
the natural course of MS obtained from patient registries.
Moreover, the fact that the immunomodulatory therapy
applied after the baseline study termination did not differ
signiﬁcantly between the three baseline groups (placebo,
interferon beta 1b 250 mg, interferon beta 1b 50 mg) also
seems to emphasize a beneﬁcial effect of interferon beta 1b
on patients' survival.
The cause of death was established in 61 (75.3%) cases – no
signiﬁcant differences were noted with respect to the cause of
death in the respective baseline groups. In 50 (82%) out of 61
cases the cause of death was associated with MS (EDSS > 7,
brain stem dysfunction, aspiration pneumonia, sepsis, respi-
ratory failure, pulmonary embolism, trauma caused by a fall,
side-effects of treatment, suicide) [27].
Not only treatment-related beneﬁts, but also certain
baseline parameters, such as lower EDSS score, smaller MRI
ventricle size and smaller T2 lesion volume were associated
with longer survival [27].
The 21-year follow-up positively veriﬁed the results
obtained after 16 years. The NNT index (Number needed to
treat) calculated on the basis of the obtained results was 7.78,
which indicates that statistically 8 patients have to be treated
with interferon beta-1b for 21 years, to prevent one fatal
outcome. For instance, NNT for statins administered for
5 years to patients with coronary disease to prevent death is
83 and for antiplatelet drugs in acute stroke to prevent death –
100 [28].
The 21-year study revealed the importance of the appro-
priate length of follow-up and showed that data should be
obtained from the highest possible percentage of originally
randomized patients [27]. In the additional 5-year-observation
period, the number of deaths doubled (35 after 16 years and
81 after 21 years). It also turned out that the mortality rate in
the initially unidentiﬁed patients was higher than that noted
among the identiﬁed cases (18.4% vs. 10.7%).period, at the beginning of the pivotal study, treated with
er HealthCare 2011; 2(2): 8–12. For writing this review article
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interferon beta-1a
4.3.1. A retrospective 15-year follow-up of patients treated
with intramuscular interferon beta-1a therapy
Patients were assessed 15 years after randomization into the
registration trial of interferon beta-1a administered intramus-
cularly in relapsing-remitting SM [29]. The study used the
EDSS; life quality and independence-related questionnaires
were applied. Data were obtained for 79% of eligible patients
(136/172). Patients currently receiving intramuscular interfer-
on beta-1a presented signiﬁcantly lower EDSS scores, less
progression to the EDSS threshold (EDSS = 6), better general
health condition and greater independence.
Fourteen patients out of 136 died, including 8 who had been
given placebo at baseline and 6 treated with interferon beta-1a.
The mean time to death since enrollment to the study showed
a tendency toward statistical signiﬁcance (p = 0.0584). In the
case of 8 patients who had been allocated to the placebo group
at baseline, the mean time to death was 7.8 years, whereas in
6 patients receiving interferon beta – 11.5 years.
4.3.2. Retrospective 8-year and 15-year follow-up studies of
patients treated with subcutaneous interferon beta-1a therapy
Patients participating in the registration trial of interferon beta-
1a administered subcutaneously 3 times a week were assessed
8 years after randomization [30]. Only 68.2% of the patients
(382/560) returned for the long-term follow-up assessment. In
the interferon beta-1a 44 mg group, patients presented with
lower EDSS score, lower annual relapse rate and smaller T2
lesion volume, as compared to the baseline placebo group. Of
382 patients who did not return for the assessment 8 years after
randomization, eight were deceased, including two assigned to
the placebo group at baseline, ﬁve taking interferon beta-1a
22 mg and one – interferon beta-1a 44 mg. Three out of these
8 deaths took place during the registration trial (not related to
the assessed drug) and the other ﬁve after its termination
(unknown cause).
In 2012, results of the assessment of mortality and its
predictors 15 years after the initial randomization into the
baseline subcutaneous interferon beta-1a group were published
as a conference report [31]. In the assessed group, there were
26 deaths; however, the mortality rate did not differ signiﬁcantly
between the 3 baseline groups (placebo, interferon 22 mg and
44 mg). Age, EDSS and T2 lesion volume at the time of
randomization were found to signiﬁcantly affect mortality.
The authors of the publication [31] managed to identify
only 291 patients from the registration study (291/560; 52%).
Thus, it cannot be excluded that among the remaining 269
patients (48%), the percentage of deaths could be even higher,
like it was in the 16-year follow-up of interferon beta-1b
therapy. Potential data obtained from the non-assessed
patients might alter the proportional distribution of deaths
in the three baseline study groups.
4.4. Long-term treatment with interferon beta and life
expectancy of patients
Only the long-term (21-year) follow-up of patients randomized
at baseline to the registration study provides mortality-relateddata, indicating a beneﬁcial effect of the drug [27]. Other long-
term observations of patients treated with interferon beta
preparations, yet substantially shorter and involving a lower
percentage of patients at baseline, almost neglect that issue.
However, in a study on intramuscular interferon beta-1a
therapy, trends in mortality seem to conﬁrm the beneﬁts of
early treatment with the drug [29]. On the other hand, a 15-year
follow-up of subcutaneous interferon beta-1a therapy that
involved only 52% of baseline trial patients does not support
this view [31].
The problem of mortality has not been raised in open
trials such as QUASIMS (Quality Assessment in Multiple Sclerosis
Therapy) [32], assessing the efﬁcacy and safety of various
interferon beta preparations. Their survey was discussed in
detail by Limmoroth et al. [33]. Most of the studies have not
revealed any signiﬁcant differences in the efﬁcacy of the
respective interferon beta preparations, which seems to
conﬁrm their similar impact on mortality rate. This, however,
requires further research.
4.5. Life expectancy and life quality
In the discussion on patients' survival, the problem of life
quality cannot be avoided. As shown in numerous reports, the
quality of life is signiﬁcantly reduced in MS patients,
undergoing gradual deterioration with progressing disability
[4,34]. However, Putzki et al. have revealed that the quality of
life is already signiﬁcantly decreased in the early phases of the
disease and that it can be improved by immunomodulatory
therapy at that stage [5].
So far, reports from the 21-year follow-up have not
elucidated whether early administration of interferon beta-
1b not only increases the chances of survival but also prevents
disability. However, the 16-year-observation has shown some
beneﬁcial impact of long-term t interferon beta-1b therapy on
disability [24]. The analysis of 3 subgroups of patients that
differed in the time of exposure to interferon beta-1 b 250 mg
(<10%; 10–79% and ≥80% of the observation period) failed to
ﬁnd statistically signiﬁcant differences in the EDSS score,
although the time from diagnosis to EDSS ≥6.0 was longer in
the group of patients with the longest exposure to the drug
(13.6 years for ≥80%, 10.5 years for 10–79% and 8.3 years for
<10% of the follow-up period). The incidence rate of the
secondary-progressive type (34.3% in the group of patients
treated <10% and 28.6% with ≥80% of the of the follow-up
period) was found to be lower (statistically insigniﬁcant) and
the time from diagnosis to that moment was prolonged
(11.4 years for <10% and 13.8 years for ≥80% of the follow-up).
The respective groups did not differ in the annual relapse rate,
which decreased in all study groups as compared to the
baseline level (1.6–1.8 to 0.3–0.6 after 15–16 years since the
commencement of the study.
Maintenance of psychophysical efﬁciency is not the only
determinant of life quality. The term ‘‘life quality’’ itself is
ambiguous and multifactorial, depending on cultural and
social differences, and general social standards [35]. Studies on
the quality of life have shown that MS patients exhibit high
level of psychological adaptation to the disease. In a Swedish
study [4] no correlation was found between the enhancement
of psychosocial problems and the disease progression. Also
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 8 ( 2 0 1 4 ) 4 3 6 – 4 4 1440research conducted in Poland using a EQ-5D questionnaire
revealed that with time patients mostly reported mobility
difﬁculties, but not anxiety/depression problems.
4.6. Safety of long-term interferon beta therapy
Safety of long-term immunomodulatory therapy in multiple
sclerosis is an equally important issue. All so far conducted
long-term studies assessing the effects of interferon beta
preparations conﬁrm their safe use [29,30,36]. The 16-year
follow-up [24] has proved the safety of long-term interferon
beta-1b therapy, with the most frequent side-effects being
ﬂu-like symptoms, fever, headaches, reactions at the site of
drug administration (necrotic lesions were not observed),
general malaise, muscle pains, slight lymphopenia and
elevated level of hepatic enzymes. The frequency of side
effects associated with interferon beta-1b therapy decreased
with time, being lower within the last 2 years of the 16-year-
follow-up as compared to the baseline (pivotal trial).
Moreover, no other new side-effects appeared after 16years
of drug administration [36]. Similar ﬁndings were reported
from an eight-year follow-up of subcutaneous interferon
beta-1a therapy [30], during which the most common were
mild or moderate reactions at the site of drug injection
(in 44%) and ﬂu-like symptoms (in 11.7% of patients).
In laboratory studies, the most frequent but usually mild
abnormalities included the elevated level of transaminases
and lymphopenia [30].
4.7. Disadvantages of retrospective trials
Although retrospective observations of patients provide
valuable information on the efﬁcacy and safety of the
treatment applied, they have a number of limitations that
hinder interpretation of results. For instance, incomplete
identiﬁcation of patients or non-returning patients can
reduce the power of the study and deform the outcome.
Another problem is lack of randomization and control, as well
as treatment adherence which is difﬁcult to reliably assess
during a long-term retrospective follow-up study. The cited
publications do not analyze this issue [24,27,29,30]. It has been
estimated that even one fourth of all SM patients do not
comply with dosing recommendations [37]. Signiﬁcantly,
many patients may also use other immunomodulatory drugs
than the one assessed, which is likely to affect both the
clinical picture of the disease and the side-effects observed.
5. Conclusion
Until now, all follow-up trials involving MS patients treated
with interferon beta have demonstrated long-term efﬁcacy of
the therapy, suggesting a positive impact of interferon beta-1b
on patients' survival. Long-term treatment with interferon
beta has proved to be safe and proper monitoring helps avoid
serious undesirable effects. According to the available data,
the interferon beta therapy should be continued as long as it is
efﬁcient and well tolerated. In the last decade, new immuno-
modulatory drugs, such as natalizumab, ﬁngolimod and
teriﬂunomid have been registered as a favorable alternativewhen interferon beta is inefﬁcient. However, data concerning
the effects of long-term treatment with these preparations are
currently missing.
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